Trial Profile
An Open-Label, Dose Finding, International Phase 2 Study With Once Monthly Subcutaneous VRS-317 in Adult Growth Hormone Deficiency (GHD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Somavaratan (Primary)
- Indications Growth disorders; Somatotropin deficiency
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms VITAL
- Sponsors Versartis
- 27 Jul 2017 According to a Versartis media release, data will be presented at the 10th Annual International Joint Meeting of Pediatric Endocrinology (IMPE) Sep 2017.
- 04 Apr 2017 Results of an ad hoc analysis on preliminary data assessing correlation between baseline IGF-I, dose, and response presented at The 99th Annual Meeting of the Endocrine Society
- 04 Apr 2017 Results presented at The 99th Annual Meeting of the Endocrine Society